Search
"Extravasation of the radiopharmaceutical during peptide receptor radionuclide therapy infusion is an unwanted infrequently reported event. We present the case of a 74-year old woman with a neuroendocrine tumor who was referred for peptide receptor radionuclide therapy" de Vries-Huizing et al (2024).

Extravasation after [177Lu]Lu-HA-DOTATATE therapy

Abstract:

Extravasation of the radiopharmaceutical during peptide receptor radionuclide therapy infusion is an unwanted infrequently reported event. We present the case of a 74-year old woman with a neuroendocrine tumor who was referred for peptide receptor radionuclide therapy. During intravenous infusion of 7.4 GBq [177Lu]Lu-HA-DOTATATE in the upper right arm, extravasation of the radiopharmaceutical occurred through a displaced intravenous catheter. Planar scintigraphy showed pooling of radioactivity in the right upper arm. After 24 hours, the swelling in the arm was decreased; however, erythema was increased. One week later, symptoms had disappeared, and the patient did not experience any complications during follow-up of 11 months.


Reference:

de Vries-Huizing DMV, Cheung ZJ, Hendrikx JJMA, Donswijk ML, Versleijen MWJ. Extravasation After [177Lu]Lu-HA-DOTATATE Therapy. Clin Nucl Med. 2024 Mar 7. doi: 10.1097/RLU.0000000000005137. Epub ahead of print. PMID: 38465961.